LabCorp Injects $2M into SynapDx for Autism Test Development | GenomeWeb

NEW YORK (GenomeWeb News) – Laboratory Corporation of America is investing $2 million in SynapDx to further its development of an autism spectrum disorder test.

The investment, announced today by SynapDx, follows a $6 million Series A1 funding round completed in December to support the Lexington, Mass.-based firm's clinical study in support of the ASD test, which is intended to help physicians identify children with ASD earlier than they can today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."